News

What do ophthalmologists consider the key advancements in treating glaucoma over the last several decades?

Emerging technologies, such as remote tonometry and genetic risk scoring, are revolutionizing glaucoma care by enabling earlier detection, personalized management, and more efficient use of resources.

If approved, the drug will be branded as LYTENAVA.

We asked ophthalmologists what stands out to them in the history of treating glaucoma and where future treatments might be heading.

The procedure offers a renewed approach to suprachoroidal drainage, with potential for both combined and standalone glaucoma surgery.

Researchers indicated that pediatric patients with Leber congenital amaurosis experienced improvements in vision.

The Elios procedure increased aqueous humor outflow in all investigated eyes, but further studies are needed to correlate these improvements with its clinical efficacy.

A systematic review and meta-analysis highlights the safety and efficacy of excimer laser trabeculostomy as an implant-free MIGS procedure for managing open-angle glaucoma and ocular hypertension, either alone or in combination with cataract surgery.

At the Envision Summit 2025 in San Juan, Puerto Rico, Sara Wester, MD, discussed the Women Leaders in Eye Health session at the conference and the donation from Orbis that supported the session.

The company announced it has successfully started imaging patients with its first prototype of its device using both near-infrared and green modes.

Ophthalmologist offers insights into the value of technology in diabetic retinopathy.

The device offers a shortened procedure time and efficient, effective SMILE for patients with myopia, with or without astigmatism.

Bonnie Henderson, MD, founder and program director of the EnVision Summit, talked with Ophthalmology Times about the evolution of the conference and how it brings optometrists and ophthalmologists together to learn, discuss shared problems, and facilitate co-management in a family-friendly environment.

Italian investigators reported that ocular surface conditions such as dry eye disease are key factors in perioperative outcomes, even when patients achieve 20/20 vision.

The funding will help further the glaucoma program alongside new board member Carol Gallagher.

Monofocal IOLs, along with advanced phacoemulsification technology, offer tailored solutions.

The biosimilar to aflibercept (Eylea) had already received approval in the EU and US.

Incoming directors bring diverse expertise to help the ASO protect ophthalmic care and advocate for patients.

At the Envision Summit 2025 in San Juan, Puerto Rico, Kristen Nwanyanwu, MD, MBA, MHS, joined by her children, discussed her talk on eradicating TRD and the family-friendly environment of the conference.

The new formula will help relieve temporary symptoms caused by dryness of the eye.

Shameema Sikder, MD; and T. Y. Alvin Liu, MD, highlight the technology’s role in bridging challenges and successes for clinical practice.

Amniotic membrane tissue offers a number of advantages to patients.

The state-of-the-art facility more than doubles the institute’s footprint, enhancing patient care, research, and education.

Clinician highlights a novel complication of atropine treatment in a teenage patient.

A PDUFA date has been set for October 20, 2025. If approved, Epoxia will be the first epi-on corneal crosslinking on the market.

At the Envision Summit 2025 in San Juan, Puerto Rico, retina program chairs Geeta Lalwani, MD, and Majda Hadziahmetovic, MD, discussed Hadziahmetovic's presentation on deep learning models of neovascular AMD as well as their time at the conference.

RPESC-RPE-4W is a cell product derived from adult retinal pigment epithelial stem cells.

Telomir Pharmaceuticals shared results from its recent preclinical studies conducted in human retinal cell lines and plans for future research.

According to Apellis and Sobi, pegcetacoplan (Aspaveli) first received marketing authorisation for treatment of paroxysmal nocturnal hemoglobinuria.

At the Envision Summit 2025 in San Juan, Puerto Rico, Mike Farkas, MD, discussed gene therapy research for retinal degenerations that sidetracks the current "status quo" therapies of AAV-based replacement and CRISPR-Cas9 genome editing.